Photo taken from Paolo Tarantino/X
Jun 7, 2024, 13:10
Paolo Tarantino: Among the ASCO24 abstracts, particularly notable was the DB03 update
Erika Hamilton shared Paolo Tarantino’s post on X, adding: ,
“Agree, I think the recognition that this is the longest Overall Survival reported in HER-2+ wasn’t recognized by all- considering these patients were getting 2nd line treatment over 4.3 years!”
Quoting Paolo Tarantino’s post:
“Among the ASCO24 abstracts, particularly notable was the DB03 update. T-DXd led to a 10-month increase in Overall Survival for pretreated HER2+ MBC, with the longest median Overall Survival ever reported (52 months). What once was the most aggressive MBC subtype, now is the one we treat best.“
Proceed to the article.
Source: Erika Hamilton/X and Paolo Tarantino/X
Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.
Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.